000306248 001__ 306248
000306248 005__ 20251118115759.0
000306248 0247_ $$2doi$$a10.3389/fonc.2021.645524
000306248 0247_ $$2pmid$$apmid:33959505
000306248 0247_ $$2pmc$$apmc:PMC8093622
000306248 037__ $$aDKFZ-2025-02477
000306248 041__ $$aEnglish
000306248 082__ $$a610
000306248 1001_ $$aMargulis, Itai$$b0
000306248 245__ $$aA Pro-Tumorigenic Effect of Heparanase 2 (Hpa2) in Thyroid Carcinoma Involves Its Localization to the Nuclear Membrane.
000306248 260__ $$aLausanne$$bFrontiers Media$$c2021
000306248 3367_ $$2DRIVER$$aarticle
000306248 3367_ $$2DataCite$$aOutput Types/Journal article
000306248 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1763463449_1939189
000306248 3367_ $$2BibTeX$$aARTICLE
000306248 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000306248 3367_ $$00$$2EndNote$$aJournal Article
000306248 500__ $$a#DKFZ-MOST-Ca198#
000306248 520__ $$aActivity of the endo-beta-glucuronidase heparanase, capable of cleaving heparan sulfate (HS), is most often elevated in many types of tumors, associating with increased tumor metastasis and decreased patients' survival. Heparanase is therefore considered to be a valid drug target, and heparanase inhibitors are being evaluated clinically in cancer patients. Heparanase 2 (Hpa2) is a close homolog of heparanase that gained very little attention, likely because it lacks HS-degrading activity typical of heparanase. The role of Hpa2 in cancer was not examined in detail. In head and neck cancer, high levels of Hpa2 are associated with decreased tumor cell dissemination to regional lymph nodes and prolonged patients' survival, suggesting that Hpa2 functions to attenuate tumor growth. Here, we examined the role of Hpa2 in normal thyroid tissue and in benign thyroid tumor, non-metastatic, and metastatic papillary thyroid carcinoma (PTC) utilizing immunostaining in correlation with clinicopathological parameters. Interestingly, we found that Hpa2 staining intensity does not significantly change in the transition from normal thyroid gland to benign, non-metastatic, or metastatic thyroid carcinoma. Remarkably, we observed that in some biopsies, Hpa2 is accumulating on the membrane (envelop) of the nucleus and termed this cellular localization NM (nuclear membrane). Notably, NM localization of Hpa2 occurred primarily in metastatic PTC and was associated with an increased number of positive (metastatic) lymph nodes collected at surgery. These results describe for the first time unrecognized localization of Hpa2 to the nuclear membrane, implying that in PTC, Hpa2 functions to promote tumor metastasis.
000306248 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000306248 650_7 $$2Other$$aheparanase 2
000306248 650_7 $$2Other$$aimmunostaining
000306248 650_7 $$2Other$$alocalization
000306248 650_7 $$2Other$$ametastasis
000306248 650_7 $$2Other$$anuclear membrane
000306248 650_7 $$2Other$$athyroid carcinoma
000306248 7001_ $$aNaroditsky, Inna$$b1
000306248 7001_ $$aGross-Cohen, Miriam$$b2
000306248 7001_ $$aIlan, Neta$$b3
000306248 7001_ $$aVlodavsky, Israel$$b4
000306248 7001_ $$aDoweck, Ilana$$b5
000306248 773__ $$0PERI:(DE-600)2649216-7$$a10.3389/fonc.2021.645524$$gVol. 11, p. 645524$$p645524$$tFrontiers in oncology$$v11$$x2234-943X$$y2021
000306248 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT ONCOL : 2022$$d2024-12-18
000306248 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000306248 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000306248 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-08T17:01:20Z
000306248 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-08T17:01:20Z
000306248 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-08-08T17:01:20Z
000306248 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-08-08T17:01:20Z
000306248 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000306248 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000306248 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-18
000306248 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000306248 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000306248 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000306248 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-18
000306248 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-18
000306248 980__ $$ajournal
000306248 980__ $$aI:(DE-He78)W500-20160331
000306248 980__ $$aI:(DE-He78)W510-20160331
000306248 9801_ $$aEXTERN4COORD